Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lattice Biologics Ltd V.LBL.H

Alternate Symbol(s):  LBLTF

Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.


TSXV:LBL.H - Post by User

Bullboard Posts
Post by movingup1on Sep 08, 2013 9:14am
251 Views
Post# 21725458

Were F UCKED

Were F UCKED
CORPORATE DEVELOPMENT
2013 Outlook
In 2012, the Company continued in its search for joint venture partners or buyers of its remaining Swedish and
Norwegian properties after deciding not to
allocate any of its remaining resources
to these properties. Any properties
not sold or optioned will be dropped as carrying costs come due.
The Company currently has a working capital deficiency of
$301,448 and will therefore need funding to continue its
operations through equity or debt financing, sale of assets, joint venture arrangements or a combination thereof.

Bullboard Posts